Considering safety and patient tolerance in the use of ketogenic diet in the management of refractory and super-refractory status epilepticus: a systematic review

被引:7
|
作者
Dozieres-Puyravel, Blandine [1 ,2 ]
Hohn, Sophie [1 ,2 ]
Auvin, Stephane [1 ,2 ,3 ]
机构
[1] Hop Robert Debre, APHP, Serv Neurol Pediat, Paris, France
[2] Univ Paris, Paris, France
[3] Inst Univ France, Paris, France
关键词
Ketogenic diet; refractory status epilepticus; super-refractory status epilepticus; NORSE; INTENSIVE-CARE-UNIT; EPILEPTOGENESIS; MULTICENTER; EPILEPSY; CHILDREN;
D O I
10.1080/14737175.2021.1956905
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Early use of the ketogenic diet (KD) is described as having a particular interest for super-refractory status epilepticus and febrile infection-related epilepsy syndrome. The authors conducted a systematic review of the available data on the KD for refractory and super-refractory status epilepticus. Areas covered Following a systematic bibliographic search, the authors found 15 published papers: 2 prospective and 13 retrospective studies. Most often, the primary aim of the retrospective studies was the efficacy evaluation of the KD for refractory or super-refractory status epilepticus. Four studies focused on the use of KD for NORSE/FIRES. These initial studies suggested that KD was effective in these conditions, and that it showed mild and manageable side effects. Expert opinion The published studies provided enough preliminary data to validate the feasibility and safety of the use of KD for refractory and super-refractory status epilepticus. Further studies demonstrating the efficacy of the KD in these indications are needed. Possible design and endpoints are discussed.
引用
收藏
页码:1303 / 1308
页数:6
相关论文
共 50 条
  • [41] Ketamine use for super-refractory status epilepticus in children
    Fung, Eva L. W.
    Yam, K. M.
    Yau, Maggie L. Y.
    HONG KONG MEDICAL JOURNAL, 2020, 26 (06) : 549 - 550
  • [42] Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults
    Martin Holtkamp
    Drugs, 2018, 78 : 307 - 326
  • [43] Commentary on Isoflurane in Refractory and Super-Refractory Status Epilepticus
    Bryan Young, G.
    NEUROCRITICAL CARE, 2021, 35 (03) : 611 - 612
  • [44] Refractory and Super-Refractory Status Epilepticus-an Update
    Hocker, Sara
    Tatum, William O.
    LaRoche, Suzette
    Freeman, W. David
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2014, 14 (06)
  • [45] Use of isoflurane as treatment for super-refractory status epilepticus
    Plans-Galvan, Oriol
    Daniel, Xavier
    Rosich, Sara
    Blazquez-Alcaide, Vanessa
    Gil-Castillejos, Diana
    Bodi, Maria
    REVISTA DE NEUROLOGIA, 2023, 76 (09) : 309 - 312
  • [46] Commentary on Isoflurane in Refractory and Super-Refractory Status Epilepticus
    G. Bryan Young
    Neurocritical Care, 2021, 35 : 611 - 612
  • [47] Treatment of Super-Refractory Status Epilepticus
    Ahmad Bayrlee
    Nimalya Ganeshalingam
    Lisa Kurczewski
    Gretchen M. Brophy
    Current Neurology and Neuroscience Reports, 2015, 15
  • [48] Super-refractory status epilepticus in adults
    Malter, Michael P.
    Neuneier, Janina
    NEUROLOGICAL RESEARCH AND PRACTICE, 2022, 4 (01):
  • [49] Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults
    Holtkamp, Martin
    DRUGS, 2018, 78 (03) : 307 - 326
  • [50] Neurostimulation in the treatment of refractory and super-refractory status epilepticus
    Trinka, Eugen
    Brigo, Francesco
    EPILEPSY & BEHAVIOR, 2019, 101